• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Efficacy of venetoclax monotherapy in patients with relapsed, refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor therapy.

作者信息

Eyre Toby A, Walter Harriet S, Iyengar Sunil, Follows George, Cross Matthew, Fox Christopher P, Hodson Andrew, Coats Josh, Narat Santosh, Morley Nick, Dyer Martin J S, Collins Graham P

机构信息

Department of Haematology, Churchill Hospital, Oxford University Hospitals NHS Foundation Trust

The Ernest and Helen Scott Haematological Research Institute, University of Leicester.

出版信息

Haematologica. 2019 Feb;104(2):e68-e71. doi: 10.3324/haematol.2018.198812. Epub 2018 Sep 6.

DOI:10.3324/haematol.2018.198812
PMID:30190341
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6355471/
Abstract
摘要

相似文献

1
Efficacy of venetoclax monotherapy in patients with relapsed, refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor therapy.维奈托克单药治疗在接受布鲁顿酪氨酸激酶抑制剂治疗后复发、难治性套细胞淋巴瘤患者中的疗效。
Haematologica. 2019 Feb;104(2):e68-e71. doi: 10.3324/haematol.2018.198812. Epub 2018 Sep 6.
2
Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma With Venetoclax: A Single-Center Evaluation of Off-Label Use.维奈托克治疗复发/难治性非霍奇金淋巴瘤的疗效：一项单中心的超适应证应用评价。
Clin Lymphoma Myeloma Leuk. 2019 Dec;19(12):791-798. doi: 10.1016/j.clml.2019.09.612. Epub 2019 Sep 28.
3
Treatment outcomes of BTK inhibitors and venetoclax with or without anti-CD20 monoclonal antibody in relapsed or refractory mantle cell lymphoma.布鲁顿酪氨酸激酶（BTK）抑制剂与维奈克拉联用或不联用抗CD20单克隆抗体治疗复发或难治性套细胞淋巴瘤的疗效
Ann Hematol. 2025 Apr;104(4):2361-2371. doi: 10.1007/s00277-025-06379-x. Epub 2025 Apr 25.
4
Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma.伊布替尼联合维奈托克治疗套细胞淋巴瘤。
N Engl J Med. 2018 Mar 29;378(13):1211-1223. doi: 10.1056/NEJMoa1715519.
5
Concurrent ibrutinib plus venetoclax in relapsed/refractory mantle cell lymphoma: the safety run-in of the phase 3 SYMPATICO study.在复发/难治性套细胞淋巴瘤中联合使用伊布替尼和维奈托克：3 期 SYMPATICO 研究的安全性预试验。
J Hematol Oncol. 2021 Oct 30;14(1):179. doi: 10.1186/s13045-021-01188-x.
6
Venetoclax to treat relapsed blastic plasmacytoid dendritic cell neoplasm: A case-report and review of literature.维奈托克治疗复发的浆细胞样树突状细胞肿瘤：一例病例报告及文献综述
Leuk Res. 2019 Oct;85:106199. doi: 10.1016/j.leukres.2019.106199. Epub 2019 Aug 5.
7
Final analysis of a phase II study of ibrutinib in Japanese patients with relapsed/refractory mantle cell lymphoma.依鲁替尼用于日本复发/难治性套细胞淋巴瘤患者的II期研究的最终分析。
J Clin Exp Hematop. 2019;59(2):98-100. doi: 10.3960/jslrt.19006.
8
Venetoclax as a single agent and in combination with PI3K-MTOR1/2 kinase inhibitors against ibrutinib sensitive and resistant mantle cell lymphoma.维奈托克作为单药以及与PI3K-MTOR1/2激酶抑制剂联合用于治疗对依鲁替尼敏感和耐药的套细胞淋巴瘤。
Br J Haematol. 2019 Jan;184(2):298-302. doi: 10.1111/bjh.15079. Epub 2018 Jan 30.
9
Diagnostically challenging immunophenotypic shift in mantle cell lymphoma following ibrutinib and venetoclax therapy.依鲁替尼和维奈托克治疗后套细胞淋巴瘤中具有诊断挑战性的免疫表型转变
Pathology. 2021 Dec;53(7):926-929. doi: 10.1016/j.pathol.2021.01.013. Epub 2021 May 1.
10
Exposure-response evaluations of venetoclax efficacy and safety in patients with non-Hodgkin lymphoma.维奈托克在非霍奇金淋巴瘤患者中的疗效和安全性的暴露-反应评估。
Leuk Lymphoma. 2018 Apr;59(4):871-879. doi: 10.1080/10428194.2017.1361024. Epub 2017 Aug 10.

引用本文的文献

1
Diagnostic and therapeutic pathways for lymphoma patients: expert consensus through Nominal Group Technique and Delphi methodology.淋巴瘤患者的诊断和治疗路径：通过名义群体技术和德尔菲法达成的专家共识
Front Oncol. 2025 Aug 13;15:1627175. doi: 10.3389/fonc.2025.1627175. eCollection 2025.
2
Resistance mechanisms and clonal dynamics in mantle cell lymphoma treated with sequential BTKi and venetoclax therapy.序贯使用布鲁顿酪氨酸激酶抑制剂（BTKi）和维奈克拉治疗套细胞淋巴瘤的耐药机制与克隆动力学
J Pathol. 2025 Aug;266(4-5):395-404. doi: 10.1002/path.6434. Epub 2025 May 15.
3
Venetoclax-based low-intensity chemotherapy in the salvage treatment of relapsed/refractory T-cell acute lymphoblastic leukemia.基于维奈托克的低强度化疗用于复发/难治性T细胞急性淋巴细胞白血病的挽救治疗
Clin Exp Med. 2025 Apr 2;25(1):104. doi: 10.1007/s10238-025-01638-7.
4
Updates on the Biological Heterogeneity of Mantle Cell Lymphoma.套细胞淋巴瘤生物学异质性的最新进展
Cancers (Basel). 2025 Feb 19;17(4):696. doi: 10.3390/cancers17040696.
5
"The End of the Golden Weather": therapeutic strategies for mantle cell lymphoma relapsed or refractory to covalent BTK inhibitors.《金色天气的终结》：套细胞淋巴瘤对共价BTK抑制剂复发或难治的治疗策略
Haematologica. 2025 Mar 1;110(3):576-587. doi: 10.3324/haematol.2024.286205.
6
The rules of T-cell engagement: current state of CAR T cells and bispecific antibodies in B-cell lymphomas.T 细胞激活的规则：嵌合抗原受体 T 细胞和双特异性抗体在 B 细胞淋巴瘤中的现状。
Blood Adv. 2024 Sep 10;8(17):4700-4710. doi: 10.1182/bloodadvances.2021004535.
7
Targeted Therapies in the Treatment of Mantle Cell Lymphoma.套细胞淋巴瘤治疗中的靶向疗法
Cancers (Basel). 2024 May 20;16(10):1937. doi: 10.3390/cancers16101937.
8
Biological and clinical determinants shaping heterogeneity in mantle cell lymphoma.塑造套细胞淋巴瘤异质性的生物学和临床决定因素。
Blood Adv. 2024 Jul 23;8(14):3652-3664. doi: 10.1182/bloodadvances.2023011763.
9
Seven-year outcomes of venetoclax-ibrutinib therapy in mantle cell lymphoma: durable responses and treatment-free remissions. Venetoclax-ibrutinib 治疗套细胞淋巴瘤的 7 年结果：持久缓解和无治疗缓解。
Blood. 2024 Aug 22;144(8):867-872. doi: 10.1182/blood.2023023388.
10
Cyclin dependent kinase 4/6 inhibitor palbociclib synergizes with BCL2 inhibitor venetoclax in experimental models of mantle cell lymphoma without RB1 deletion.细胞周期蛋白依赖性激酶4/6抑制剂帕博西尼与BCL2抑制剂维奈托克在无RB1缺失的套细胞淋巴瘤实验模型中具有协同作用。
Exp Hematol Oncol. 2024 Mar 25;13(1):34. doi: 10.1186/s40164-024-00499-2.

本文引用的文献

1
Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma.伊布替尼联合维奈托克治疗套细胞淋巴瘤。
N Engl J Med. 2018 Mar 29;378(13):1211-1223. doi: 10.1056/NEJMoa1715519.
2
Ibrutinib resistance in mantle cell lymphoma: clinical, molecular and treatment aspects.套细胞淋巴瘤伊布替尼耐药：临床、分子和治疗方面。
Br J Haematol. 2018 May;181(3):306-319. doi: 10.1111/bjh.15108. Epub 2018 Jan 23.
3
Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial.依鲁替尼治疗后进展的慢性淋巴细胞白血病的维奈托克：多中心、开放标签、2 期试验的中期分析。
Lancet Oncol. 2018 Jan;19(1):65-75. doi: 10.1016/S1470-2045(17)30909-9. Epub 2017 Dec 12.
4
Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial.阿卡替尼治疗复发或难治性套细胞淋巴瘤（ACE-LY-004）：一项单臂、多中心、2 期临床试验。
Lancet. 2018 Feb 17;391(10121):659-667. doi: 10.1016/S0140-6736(17)33108-2. Epub 2017 Dec 11.
5
Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma.维奈托克在复发或难治性非霍奇金淋巴瘤患者中的I期首次人体研究。
J Clin Oncol. 2017 Mar 10;35(8):826-833. doi: 10.1200/JCO.2016.70.4320. Epub 2017 Jan 17.
6
Predictive factors and outcomes for ibrutinib therapy in relapsed/refractory mantle cell lymphoma-a "real world" study.复发/难治性套细胞淋巴瘤中依鲁替尼治疗的预测因素及结果——一项“真实世界”研究
Hematol Oncol. 2017 Dec;35(4):528-535. doi: 10.1002/hon.2380. Epub 2017 Jan 8.
7
FBXO10 deficiency and BTK activation upregulate BCL2 expression in mantle cell lymphoma.FBXO10缺陷和BTK激活上调套细胞淋巴瘤中BCL2的表达。
Oncogene. 2016 Dec 1;35(48):6223-6234. doi: 10.1038/onc.2016.155. Epub 2016 May 9.
8
Postibrutinib outcomes in patients with mantle cell lymphoma.套细胞淋巴瘤患者接受伊布替尼治疗后的结局。
Blood. 2016 Mar 24;127(12):1559-63. doi: 10.1182/blood-2015-10-673145. Epub 2016 Jan 13.
9
Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes.套细胞淋巴瘤患者伊布替尼治疗失败后，不太可能对挽救性化疗有反应，且预后不良。
Ann Oncol. 2015 Jun;26(6):1175-1179. doi: 10.1093/annonc/mdv111. Epub 2015 Feb 23.
10
Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.伊布替尼治疗复发或难治性套细胞淋巴瘤中的 BTK。
N Engl J Med. 2013 Aug 8;369(6):507-16. doi: 10.1056/NEJMoa1306220. Epub 2013 Jun 19.